18.9 C
New York
Tuesday, May 18, 2021

Novartis immuno-oncology drug candidate fails skin cancer trial

Must read

Tata Motors Q4 takeaways: Outlook challenging, but recovery still on track

“The business has demonstrated strong resilience in the face of adversity and its fundamentals are strong,” the company said in its earnings statement in...

JPMorgan appoints top job contenders as co-heads of consumer business

Stock Markets6 minutes ago (May 18, 2021 10:36AM ET) 2/2 (C) Reuters. FILE PHOTO: A JPMorgan Chase & Co building is shown in Irvine, California, U.S.,...

CVS taps former Aetna executive as chief financial officer

Stock Markets7 minutes ago (May 18, 2021 10:35AM ET) (C) Reuters. FILE PHOTO: The CVS logo is seen at one of their stores in Manhattan,...

U.S. lawmakers urge Facebook to drop Instagram for kids plan

Stock Markets10 minutes ago (May 18, 2021 10:32AM ET) (C) Reuters. FILE PHOTO: Silhouettes of mobile users are seen next to a screen projection of...
imageStock Markets1 hour ago (Aug 22, 2020 03:20AM ET)

(C) Reuters. The logo of Swiss drugmaker Novartis is pictured at the French company’s headquarters in Rueil-Malmaison

ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer.

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Despite the failure, Novartis is continuing development of spartalizumab, a so-called checkpoint inhibitor thought to help take the brakes off the immune system in fighting cancer, against other kind of tumors, the Basel-based company said.

Novartis has been late in developing such immuno-oncology drugs for its portfolio, a field now dominated by lucrative medicines including Merck’s Keytruda, Bristol-Myers Squibb (NYSE:BMY)’s Opdivo, and to a lesser extent, Roche’s Tecentriq.

Novartis immuno-oncology drug candidate fails skin cancer trial

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

- Advertisement -

Latest article

Tata Motors Q4 takeaways: Outlook challenging, but recovery still on track

“The business has demonstrated strong resilience in the face of adversity and its fundamentals are strong,” the company said in its earnings statement in...

JPMorgan appoints top job contenders as co-heads of consumer business

Stock Markets6 minutes ago (May 18, 2021 10:36AM ET) 2/2 (C) Reuters. FILE PHOTO: A JPMorgan Chase & Co building is shown in Irvine, California, U.S.,...

CVS taps former Aetna executive as chief financial officer

Stock Markets7 minutes ago (May 18, 2021 10:35AM ET) (C) Reuters. FILE PHOTO: The CVS logo is seen at one of their stores in Manhattan,...

U.S. lawmakers urge Facebook to drop Instagram for kids plan

Stock Markets10 minutes ago (May 18, 2021 10:32AM ET) (C) Reuters. FILE PHOTO: Silhouettes of mobile users are seen next to a screen projection of...

Macy’s boosts forecasts as vaccines encourage in-store shopping

Economy10 minutes ago (May 18, 2021 10:32AM ET) (C) Reuters. FILE PHOTO: Shoppers are seen outside Macy's in the Manhattan borough of New York City,...